8-K: Sonnet BioTherapeutics Completes Enrollment and Initiates Dosing in Phase 1 Trial of SON-1010 for Advanced Solid Tumors

Sonnet BioTherapeutics has completed enrollment and initiated dosing in its Phase 1 clinical trial of SON-1010 for adult patients with advanced solid tumors, with topline data expected in Q4 2024.

Summary

• Sonnet BioTherapeutics has completed enrollment and begun dosing in its Phase 1 SB101 clinical trial of SON-1010 (IL12-FHAB) for adult patients with advanced solid tumors.
• The company expects to report topline data from this study in Q4 2024.
• The SB101 trial is an open-label, adaptive-design dose-escalation study to assess the safety, tolerability, and PK/PD of SON-1010.
• The study enrolled 24 subjects.
• Primary outcome measures include evaluating the safety and tolerability of SON-1010 and establishing the maximum tolerated dose (MTD).
• SON-1010 is a proprietary version of recombinant human interleukin-12 (rhIL-12) using the company's Fully Human Albumin Binding (FHAB) platform.
• The FHAB platform extends the half-life and activity of IL-12 and targets the tumor microenvironment.
• The trial uses a desensitizing first dose to minimize toxicity and allow higher maintenance doses.
• No dose-limiting toxicities have occurred to date, and most adverse events have been mild and transient.
• One patient with progressive endometrial sarcoma had stable disease for almost 2 years on SON-1010 monotherapy.
• Cytokine analysis showed controlled and prolonged induction of interferon gamma (IFN) with minimal signals for other cytokines and no indication of cytokine release syndrome.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the completion of enrollment and initiation of dosing in the Phase 1 trial, along with encouraging safety and tolerability data. However, it also acknowledges the risks and uncertainties associated with clinical trials and future development.

Positives

• The completion of enrollment and initiation of dosing in the Phase 1 trial is a significant milestone for the company.
• The safety and tolerability of SON-1010 have been within expected levels so far.
• No dose-limiting toxicities have been observed, and adverse events have been mostly mild and transient.
• The FHAB platform is designed to improve the safety and efficacy of immune modulating biologic drugs.
• The study has shown promising results in one patient with stable disease for almost 2 years.
• Cytokine analysis indicates a controlled and prolonged induction of interferon gamma (IFN) with minimal signals for other cytokines.

Negatives

• The study is still in Phase 1, and the optimal dose of SON-1010 is yet to be determined.
• The patient with stable disease did not achieve a partial response according to RECIST rules.
• The company is seeking partnership opportunities to support a Phase 2 trial for SON-080.

Risks

• The outcome of the clinical trials is uncertain, and results may not be as expected.
• The company's cash runway is subject to change.
• There are risks associated with product development, clinical and regulatory timelines.
• The company faces competition in the market.
• Actual results may differ materially from forward-looking statements due to various factors.

Future Outlook

The company expects to report topline safety data from the Phase 1 SB101 study in Q4 2024 and is planning for potential combinations with other immunotherapies and the future development of bispecific candidates using the FHAB platform.

Management Comments

• Pankaj Mohan, Founder and Chief Executive Officer of Sonnet, stated that this milestone is an important step forward in their development program for SON-1010 as a monotherapy.
• He also mentioned that they are encouraged by the data seen to date demonstrating safety and tolerability being well within expected levels.
• He expressed hope that they will continue to see extended PK/PD, tumor targeting and clinical activity during treatment.
• He also stated that they remain committed to bringing this trial to completion.

Industry Context

This announcement is relevant to the broader trend of developing targeted immunotherapies for cancer treatment, particularly those that aim to turn 'cold' tumors 'hot' by stimulating the immune system. The use of the FHAB platform to enhance the delivery and efficacy of IL-12 is also a notable development in the field.

Comparison to Industry Standards

• The use of a desensitizing first dose to minimize toxicity is a common practice in early-stage oncology trials, particularly with agents like rhIL-12 that can cause tachyphylaxis.
• The 3+3 dose escalation design is a standard approach for determining the maximum tolerated dose (MTD) in Phase 1 oncology trials.
• The focus on safety, tolerability, and PK/PD in the Phase 1 study is consistent with industry standards for early-stage clinical trials.
• The use of a proprietary platform like FHAB to improve drug delivery and efficacy is a common strategy in the biotechnology industry.
• Companies like Roche are also exploring combination therapies with immunotherapies, as evidenced by Sonnet's collaboration with Roche on a study combining SON-1010 with atezolizumab.

Stakeholder Impact

• Shareholders may view the completion of enrollment and initiation of dosing as a positive development.
• Patients with advanced solid tumors may benefit from the potential of SON-1010 as a new treatment option.
• Employees of Sonnet BioTherapeutics are likely to be encouraged by the progress of the clinical trial.
• The company's partners and collaborators may be interested in the results of the study.

Next Steps

• The company will continue to monitor the safety and efficacy of SON-1010 in the ongoing Phase 1 trial.
• Topline safety data from the SB101 Phase 1 study is expected in Q4 2024.
• The company plans to explore potential combinations with other immunotherapies.
• The company will continue the development of bispecific candidates using the FHAB platform.

Key Dates

Keywords

SON-1010, IL12-FHAB, clinical trial, Phase 1, solid tumors, immunotherapy, FHAB, oncology, dose escalation, safety, tolerability, cytokines, interferon gamma, tumor microenvironment